Offc Action Outgoing

RSM

Finch Therapeutics, Inc.

U.S. Trademark Registration No. 88129597 - RSM - 112933-0009

To:	Finch Therapeutics, Inc. (trademarks@morganlewis.com)
Subject:	U.S. Trademark Registration No. 88129597 - RSM - 112933-0009
Sent:	08/19/19 12:25:50 PM
Sent As:	ecomitu@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

U.S. Application Serial No. 88129597

Mark: RSM

Correspondence Address:

RACHELLE A. DUBOW, ESQUIRE

MORGAN, LEWIS & BOCKIUS LLP

1 FEDERAL ST, ATTN: TMSU

BOSTON, MA 02110

Applicant: Finch Therapeutics, Inc.

Reference/Docket No. 112933-0009

Correspondence Email Address:

trademarks@morganlewis.com

NOTICE THAT PROCESSING OF

REQUEST TO DIVIDE APPLICATION IS COMPLETED

No Response Required

Issue date: August 19, 2019

DIVISIONAL COMPLETED

The request to divide application serial no. 88129597 filed on July 25, 2019, has been processed as follows:

(1) Parent (original) application serial no. 88/129,597 contains the following goods:

Class 5: Pharmaceuticals used to maintain health or restore health to a human or animal subject via treatment of a disturbed microbial community; dietary and nutritional supplements; nutritional food additives in the nature of dietary supplements for medical purposes; diagnostic agents for medical purposes for assessing whether a human or animal subject has a disturbed microbial community; biological preparations in the nature of microorganisms used to maintain health or restore health to a human or animal subject via treatment of a disturbed microbial community; cultures and preparations of microorganisms for medical and veterinary purposes; pharmaceutical and biopharmaceutical agents, namely, microbiologics, immunotherapeutics, and other therapeutic agents for the prevention and treatment of human diseases, namely, infectious disease, autoimmune disease, inflammatory disease, immune disorders, allergic disorders, cancer, immuno-oncology, metabolic disorders, digestive disorders, neurological disorders, and cardiovascular disorders; pharmaceuticals in the nature of cultures of microorganisms for medical and veterinary use.

To avoid abandonment, applicant must continue to file requests for extension of time to file a statement of use (extension requests) or a statement of use within the six-month period after the issuance of the notice of allowance or before expiration of a previously granted extension period. 37 C.F.R. §§2.88(a), 2.89(a)-(b).

(2) Child application serial no. 88/975,683 contains the following services:

Class 42: Research and development of microbiologics, immunotherapeutics, and other therapeutic agents; development of pharmaceuticals, diagnostics, food additives, dietary supplements, medical foods, foods for special dietary use; scientific research and development services relating to foods and dietary supplements; providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto.

A statement of use filed on July 25, 2019, meets the minimum filing requirements and has been placed in the child application. The statement of use will be routed to the examining attorney for examination and, if it does not meet all the statutory requirements, the examining attorney will notify the applicant. 37 C.F.R. §2.87; see TMEP §§1110 et seq.

Please call the undersigned with any questions.

TEAS PLUS OR TEAS REDUCED FEE (TEAS RF) APPLICANTS – TO MAINTAIN LOWER FEE, ADDITIONAL REQUIREMENTS MUST BE MET, INCLUDING SUBMITTING DOCUMENTS ONLINE: Applicants who filed their application online using the lower-fee TEAS Plus or TEAS RF application form must (1) file certain documents online using TEAS, including responses to Office actions (see TMEP §§819.02(b), 820.02(b) for a complete list of these documents); (2) maintain a valid e-mail correspondence address; and (3) agree to receive correspondence from the USPTO by e-mail throughout the prosecution of the application. See 37 C.F.R. §§2.22(b), 2.23(b); TMEP §§819, 820. TEAS Plus or TEAS RF applicants who do not meet these requirements must submit an additional processing fee of $125 per class of goods and/or services. 37 C.F.R. §§2.6(a)(1)(v), 2.22(c), 2.23(c); TMEP §§819.04, 820.04. However, in certain situations, TEAS Plus or TEAS RF applicants may respond to an Office action by authorizing an examiner’s amendment by telephone or e-mail without incurring this additional fee.

Direct questions about this notice to the assigned Intent-to-use staff member below.

/Lynette Patterson/

Paralegal Specialist

Office of Trademark Services

ITU/Divisional Unit

Phone - (571) 272-9507

lynette.patterson@uspto.gov

U.S. Trademark Registration No. 88129597 - RSM - 112933-0009

To:	Finch Therapeutics, Inc. (trademarks@morganlewis.com)
Subject:	U.S. Trademark Registration No. 88129597 - RSM - 112933-0009
Sent:	08/19/19 12:25:50 PM
Sent As:	ecomitu@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

USPTO Official Notice

Office action (Official Letter) or Notice has issued
on 08/19/2019 for
U.S.Trademark Application Serial No. 88975683

Your trademark document has been reviewed by an Intent-to-use staff member. As part of that review, the assigned staff member has issued you an official letter or notice. If a response is required, you must respond by the specified deadline or your application will be abandoned. Please follow the steps below.

(1) Read the official letter or notice.

(2) Direct questions about the contents of the official letter or notice to the staff member identified in the letter. Direct questions about navigating USPTO electronic forms, the USPTO website , the registration maintenance process, the status of your registration, and/or whether there are outstanding deadlines or documents related to your file to the Trademark Assistance Center (TAC).

(3) Response may be required. Carefully review the Office action to determine (1) if a response is required, (2) the applicable response time period, and (3) how to respond using the Trademark Electronic Application System (TEAS). The response must be received by the USPTO before midnight Eastern Time of the last day of the response period.

GENERAL GUIDANCE

Check the status of your application periodically in the Trademark Status & Document Retrieval (TSDR) database to avoid missing critical deadlines.
Update your correspondence email address , if needed, to ensure you receive important USPTO notices about your application.
Beware of misleading notices sent by private companies about your application.
Private companies not associated with the USPTO often use public information provided in USPTO trademark applications to mail and email trademark?related offers and notices?most of which require fees. These companies often have names similar to the USPTO. All official USPTO correspondence will only be emailed from the domain "@uspto.gov." For a current list of companies the USPTO has received complaints about, information on how to identify these offers and notices, and what to do if you receive one, see the misleading notices webpage.